

## PRESS RELEASE

Otočec

9 July 2026

The AGM of Krka, tovarna zdravil, d. d., Novo mesto (Slovenia), assembled at Hotel Otočec today for its 32nd regular meeting. The President of the Management Board and CEO, Jože Colarič, presented the Krka Group's key business results for 2025 and an estimate of the selected operating results for the first half of 2026. He stated: 'We performed very successfully in the first half of the year. Estimated revenue reached €1,119.3 million, up 7%. We increased revenue in five sales regions and most of our markets. Generally, operating results for the first half of the year have been the best since incorporation. Operating profit (EBIT) increased by 20% to €309.2 million. Net profit increased as well, exceeding €260 million. EBITDA margin stood at 31.9%. We expanded our product portfolio with six prescription pharmaceuticals and one product for companion animals. We continued all key investment projects in Slovenia and abroad, aiming to increase manufacturing capacity and strengthen our vertically integrated business model. The Supervisory Board is scheduled to discuss unaudited operating results of Krka and the Krka Group for the first half of 2026 at its regular meeting on 22 July, and we plan to publish a press release on the following day. The performance estimate for the first half of 2026 indicates we will achieve our annual plan targets by the end of the year.'

The AGM continues with the shareholders voting on the proposed resolutions. The information on the adopted resolutions follows in a separate press release.

### Krka Group estimated operating results for H1 2026

#### Highlights


€ million	Estimate Jan–Jun 2026	Jan–Jun 2025	Index
Revenue	1,119.3	1,048.5	107
– Of which revenue from sales of products and services	1,113.8	1,045.8	107
Earnings before interest, tax, depreciation and amortisation (EBITDA)	357.5	303.3	118
Operating profit (EBIT)	309.2	257.0	120
Net profit	260.2	246.7	105
<b>Ratios</b>			
EBITDA margin	31.9%	28.9%	
EBIT margin	27.6%	24.5%	
Net profit margin (ROS)	23.2%	23.5%	

#### Sales

##### Estimated product and service sales by region

€ million	Estimate Jan–Jun 2026	Jan–Jun 2025	Index
Region Slovenia	68.2	64.4	106
Region South-East Europe	159.4	148.2	108
Region East Europe	405.2	370.4	109
Region Central Europe	256.9	242.5	106
Region West Europe	181.9	187.0	97
Region Overseas Markets	42.2	33.2	127
<b>Total</b>	<b>1,113.8</b>	<b>1,045.8</b>	<b>107</b>

## Estimated product and service sales by region for H1 2026



The figures in parentheses show year-on-year changes in sales by region.

The Group's largest sales region was Region East Europe, recording product sales of €405.2 million. Product sales in the Russian Federation, our largest individual sales market, totalled €251.2 million, up 15% year on year. In Ukraine, product sales totalled €53.1 million, up 7% year on year. We also recorded sales growth in most other markets across eastern Europe and central Asia.

Region Central Europe followed with product sales of €256.9 million. Poland, our second largest individual sales market generated €128.2 million in product sales, a 5% year-on-year increase. Product sales amounted to €36.7 million (up 7%) in Czechia, and €31.0 million (up 11%) in Hungary. We also recorded sales growth in all other regional markets.

Generating €181.9 million, Region West Europe was the third largest sales region. In Germany, the largest regional sales market, product sales amounted to €47.1 million, on par with the same period last year. Our regional sales saw the highest increases in Ireland (up 6%) and Portugal (up 4%).

Region South-East Europe generated product sales of €159.4 million. We increased sales in all regional markets. In Romania, product sales totalled €40.6 million, up 1% year on year.


Product and service sales in Region Slovenia totalled €68.2 million. According to the latest available data for the first half of 2026, we retained the leading position among pharmaceutical suppliers, holding a 7.5% share of the Slovenian market.

Sales growth in Region Overseas Markets was primarily driven by higher sales in the Far East and African markets.

## Estimated product and service sales by group

€ million	Estimate Jan–Jun 2026	Jan–Jun 2025	Index
Human health products	1,020.4	956.2	107
– Prescription pharmaceuticals	943.9	878.3	107
– Non-prescription products	76.4	77.9	98
Animal health products	66.8	63.4	105
Health resort and tourist services	26.6	26.2	101
<b>Total</b>	<b>1,113.8</b>	<b>1,045.8</b>	<b>107</b>

## Estimated product and service sales by group for H1 2026



The figures in parentheses show year-on-year changes in sales by product and service group.

### New products and marketing authorisations of the Krka Group

In the first half of 2026, we expanded Krka's portfolio with seven new products: six prescription pharmaceuticals and one animal health product for companion animals. We finalised over 300 registration procedures for new and already established products in several markets.

We obtained first marketing authorisations for two new antidiabetic agents: Mempoglyn (empagliflozin/metformin) and Lymerezo (linagliptin/metformin). The agents in film-coated tablets combine active substances with the synergistic effect for a contemporary and comprehensive approach to the treatment of type 2 diabetes, allowing for patient-tailored therapy. We obtained marketing authorisations for our cardiovascular agent Co-Pitavador (pitavastatin/ezetimibe), a single-pill combination for the treatment of patients with severe hyperlipidaemia. Marketing authorisations were also granted for a new formulation of Dulsevia (duloxetine) hard gastro-resistant capsules, in some markets available as Loxentia. This established medicine is used in several therapeutic areas, primarily to treat central nervous system disorders like depression and anxiety, as well as pain caused by nerve damage associated with diabetes (diabetic peripheral neuropathy) in adults. Also, we obtained marketing authorisations in China for two new products: a single-pill combination of bisoprolol and amlodipine, and film-coated tablets containing edoxaban. These approvals further strengthened our presence in the treatment of chronic non-communicable diseases.

We expanded the range of animal health products for companion animals with marketing authorisation for our new product Robexera (robenacoxib) chewable tablets for cats, in certain markets available as Rogiola. It is used to control pain and inflammation associated with musculoskeletal diseases and relieve moderate pain and inflammation after surgery.

### Investments

According to estimates, the Krka Group allocated €52.8 million to investments in the first half of 2026, of which €41.8 million to the controlling company.

### Employees

At the end of June 2026, the Krka Group had 13,300 employees on its payroll, a 0.5% increase from the beginning of the year. Of these, 5,565 (42%) worked outside Slovenia. Overall, 48% of employees held at least a university degree, of whom 206 held doctoral degrees.



### **Investor and share information**

At the end of June 2026, Krka had 49,212 shareholders. On 30 June 2026, the Krka share traded at €250.50 on the Ljubljana Stock Exchange, up 23% on year-end 2025, when it traded at €203.00. Market capitalisation, including treasury shares, stood at €8.2 billion as at 30 June 2026.

In the first half of 2026, Krka acquired 81,754 treasury shares and held 2,516,581 treasury shares as at 30 June 2026, representing 7.674% of its share capital.

### **Krka Group objectives for 2026**

This year, the Krka Group projects revenue at €2,144 million and net profit at €405 million. We plan to invest just over €140 million, primarily in expanding and modernising production facilities and infrastructure. Construction of production facilities at Krka Pharma Private Limited, our joint venture in India, is progressing as planned.

Press release on the 2026 performance estimates is due on 12 November 2026. Based on current estimates, we expect to meet our annual objectives by the end of the year.